BridgeBio Pharma, Inc. Common Stock
Here’s whether BridgeBio Pharma, Inc. Common Stock (BBIO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.09% over 10 days); RSI 61 — healthy momentum range; strong 1-year return of +84.0%; 3-month momentum positive (+14.7%). Concerns: declining volume on rally — weak conviction (0.52x 30d avg). Currently 10.1% off its 52-week high. Score: +6/7.
BBIO is in a confirmed uptrend, trading above both its 50-day ($72.53) and 200-day ($70.68) moving averages. An RSI of 60.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +84.0% compares to +16.5% for SPY (beat the market by 67.5%).